相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan
Fumiaki Ueno et al.
JOURNAL OF GASTROENTEROLOGY (2013)
Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease
M. Chaparro et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Adalimumab in steroid-dependent Crohn's disease patients: Prognostic factors for clinical benefit
Ambrogio Orlando et al.
INFLAMMATORY BOWEL DISEASES (2012)
Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease
Akira Andoh et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Review article: infliximab for Crohn's disease treatment - shifting therapeutic strategies after 10 years of clinical experience
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L. S. Kiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Dosage Adjustment During Long-term Adalimumab Treatment for Crohn's Disease: Clinical Efficacy and Pharmacoeconomics
William J. Sandborn et al.
INFLAMMATORY BOWEL DISEASES (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Clinical Scenarios in IBD: Optimizing the Use of Conventional and Biologic Agents
Stephen B. Hanauer et al.
INFLAMMATORY BOWEL DISEASES (2010)
Evolving paradigms in the pathogenesis of IBD
Lloyd Mayer
JOURNAL OF GASTROENTEROLOGY (2010)
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies
M. Allez et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms
G. M. Bartelds et al.
ARTHRITIS AND RHEUMATISM (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Incidence and Clinical Significance of Immunogenicity to Infliximab in Crohn's Disease: A Critical Systematic Review
Andrea Cassinotti et al.
INFLAMMATORY BOWEL DISEASES (2009)
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease
R. L. West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence and Importance of Antibody Responses to Infliximab After Maintenance or Episodic Treatment in Crohn's Disease
Stephen B. Hanauer et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
分享论文
